Condition: Allergen Immunotherapy · Sponsor: Immunomic Therapeutics, Inc.
This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan. The main goals are to find out if ITI-9001 is safe, how well people tolerate it, and whether it can trigger helpful immune responses.
This description comes directly from the study's public registry record.
Scott Wehage, M.S. · 301-968-3501 · clinicaloperations@immunomix.com
Always discuss trial participation with your own doctor first.
| Medical Corporation Shinanokai SHINANOZAKA Clinic | Tokyo, Shinjuku-ku, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07726147